Pharma Could Be Going Back To Negotiating Table On Federal Drug Cost Cuts

After its protracted deal-making on the health care reform bill in 2009 and 2010, the biopharmaceutical industry may be headed back to negotiations with the White House on proposals to cut drug spending in Medicare.